Snapshot · Huberman Lab
In the famous Nun Study, some nuns whose brains showed Alzheimer's plaques and tangles post-mortem were still cognitively high-functioning before death, suggesting lifestyle and purpose can offset neurological damage.
Where this was said
At 51:12 · chapter starts 49:01
The popular assumption that memory decline is uniform and inevitable with age gets dismantled early. Castel points to the Nun Study as the most compelling challenge to the hardware-is-destiny view: nuns whose brains showed the plaques and tangles of advanced Alzheimer's were, in life, cognitively high-functioning — something else, likely purpose, social engagement, sleep, and exercise, was compensating for the neurological damage. He outlines the diversity of aging: a cognitively sharp 100-year-old and a struggling 60-year-old can coexist in the same population. The lighter corollary — why older adults retell the same joke — comes down to source memory, the ability to remember who you told something to. It fades earlier than the joke itself, so the content survives but the audience attribution doesn't. Add nostalgia, the pleasure of a good story, and maybe a touch of uninhibited repetition, and the behaviour makes complete sense.
The hippocampus shrinks 1–2% per year after midlife. But in a randomised controlled study, people assigned to walk 40 minutes, 3–4 times a week, actually grew their hippocampus by 1% — and their memory improved measurably a year later. A stretching control group showed no such effect.
Animals first sensed light 540 million years ago, triggering an evolutionary acceleration known as the Cambrian explosion within 10 million years.
It is estimated that half of all cortical activity in the human brain is involved in visual function, underscoring vision's central role in intelligence.
Cognitive neuroscience literature shows that by age 6, humans can recognize tens of thousands of different object categories — far more data than early AI systems were trained on.
Only about 3% of FDA-approved drugs have genuinely unclear mechanisms of action, making an unknown mechanism a meaningful early red flag for any compound.
Even compounds that clear preclinical testing often fail in humans: 30 to 50% of drugs entering phase 1 trials do not advance to phase 2, frequently because human behavior differs from animal models.
More than 80% of published BPC-157 research comes from a single academic group whose researchers have IP and commercial interests connected to the molecule, limiting independent replication.
Roughly 100 peptide drugs are already FDA-approved, about 150 more are in clinical trials, and 600–700 are in preclinical development, underscoring the legitimacy of peptide science broadly.
The scientist who discovered BPC-157 refused to disclose the screening method used to identify the compound and has never fully published the parent protein sequence — what Peter Attia calls 'scientific trust me, bro.'
The brain's visual, auditory, and motor cortices light up nearly identically whether an experience is real or imagined, making visualization a form of actual neural training.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.